TD Asset Management’s Lyell Immunopharma LYEL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $444K | Sell |
50,232
-954,410
| -95% | -$8.44M | ﹤0.01% | 1142 |
|
|
2025
Q1 | $540K | Hold |
1,004,642
| – | – | ﹤0.01% | 1137 |
|
|
2024
Q4 | $643K | Hold |
1,004,642
| – | – | ﹤0.01% | 1162 |
|
|
2024
Q3 | $1.52M | Hold |
1,004,642
| – | – | ﹤0.01% | 1113 |
|
|
2024
Q2 | $1.46M | Buy |
1,004,642
+40,800
| +4% | +$59.2K | ﹤0.01% | 1084 |
|
|
2024
Q1 | $2.15M | Buy |
963,842
+47,610
| +5% | +$106K | ﹤0.01% | 996 |
|
|
2023
Q4 | $1.78M | Hold |
916,232
| – | – | ﹤0.01% | 1047 |
|
|
2023
Q3 | $1.35M | Buy |
916,232
+484,316
| +112% | +$712K | ﹤0.01% | 1068 |
|
|
2023
Q2 | $1.37M | Buy |
431,916
+252,227
| +140% | +$802K | ﹤0.01% | 1057 |
|
|
2023
Q1 | $424K | Hold |
179,689
| – | – | ﹤0.01% | 1298 |
|
|
2022
Q4 | $624K | Hold |
179,689
| – | – | ﹤0.01% | 1240 |
|
|
2022
Q3 | $1.33M | Hold |
179,689
| – | – | ﹤0.01% | 1113 |
|
|
2022
Q2 | $1.17M | Hold |
179,689
| – | – | ﹤0.01% | 1152 |
|
|
2022
Q1 | $907K | Buy |
179,689
+11,000
| +7% | +$55.5K | ﹤0.01% | 1250 |
|
|
2021
Q4 | $1.31M | Buy |
168,689
+56,049
| +50% | +$434K | ﹤0.01% | 1231 |
|
|
2021
Q3 | $1.67M | Buy |
112,640
+26,151
| +30% | +$387K | ﹤0.01% | 1135 |
|
|
2021
Q2 | $1.25M | Buy |
+86,489
| New | +$1.25M | ﹤0.01% | 1210 |
|